University Of Chicago Medical Center
- Type
- Non-covered entity
- Where
- CHICAGO, IL
- Received
- $9,220,958 in 752 records, 2019 to 2025 ($0 general, $9,220,958 research)
- Source
- CMS Open Payments search ↗
On this site
- Business registration: The University of Chicago Medical Center Fuzzy (name and state)
- Business registration: UNIVERSITY OF CHICAGO MEDICAL CENTER Fuzzy (name and state)
- Plan sponsor: UNIVERSITY OF CHICAGO MEDICAL CENTER Fuzzy (name and state)
- Federal award recipient: THE UNIVERSITY OF CHICAGO MEDICAL CENTER Fuzzy (name and state)
- Lobbying client: THE UNIVERSITY OF CHICAGO MEDICAL CENTER Fuzzy (name and state)
- Lobbying client: UNIVERSITY OF CHICAGO MEDICAL CENTER Fuzzy (name and state)
- Nonprofit: UNIVERSITY OF CHICAGO MEDICAL CENTER Fuzzy (name and state)
- Trademark owner: The University of Chicago Medical Center Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | Research payment | 164 | $1,618,396 |
| 2024 | Research payment | 95 | $1,155,044 |
| 2023 | Research payment | 122 | $986,453 |
| 2022 | Research payment | 163 | $1,218,604 |
| 2021 | Research payment | 116 | $2,632,796 |
| 2020 | Research payment | 52 | $1,055,401 |
| 2019 | Research payment | 40 | $554,260 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| SEAGEN INC. | 365 | $3,178,670 | 2019–2023 |
| Amgen Inc. | 12 | $2,225,287 | 2019–2022 |
| Merck Sharp & Dohme LLC | 26 | $1,992,466 | 2022–2025 |
| Boston Scientific Corporation | 54 | $390,735 | 2019–2024 |
| Novartis Pharmaceuticals Corporation | 20 | $296,083 | 2021–2025 |
| E.R. Squibb & Sons, L.L.C. | 12 | $266,637 | 2020–2025 |
| Adaptive Biotechnologies Corporation | 89 | $159,600 | 2024–2025 |
| PFIZER INC. | 16 | $146,279 | 2022–2024 |
| Epizyme, Inc. | 82 | $106,705 | 2023–2025 |
| Deciphera Pharmaceuticals Inc. | 1 | $106,666 | 2020 |
| PUMA BIOTECHNOLOGY, INC. | 3 | $83,512 | 2025 |
| ABBVIE INC. | 5 | $57,272 | 2023–2024 |
| Syndax Pharmaceuticals, Inc. | 21 | $51,378 | 2025 |
| Iovance Biotherapeutics, Inc. | 1 | $48,442 | 2025 |
| TAIHO ONCOLOGY, INC. | 17 | $41,585 | 2022–2024 |
| Celgene Corporation | 1 | $36,125 | 2020 |
| Philips North America LLC | 4 | $29,200 | 2019 |
| CSL Behring | 3 | $2,948 | 2025 |
| EMD Serono, Inc. | 18 | $1,186 | 2020–2022 |
| UCB SA | 1 | $159 | 2021 |
| GUERBET LLC | 1 | $13 | 2022 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 752 | $9,220,958 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-31 | Merck Sharp & Dohme LLC | $529,861 | Research payment | In-kind items and services | WELIREG Drug, ONCOLOGY | A Multicenter, Open-label, Randomized, Phase 1,2 Study of Belzutifan in Combination with Palbociclib Versus Belzutifan M | 2025 |
| 2025-12-31 | Merck Sharp & Dohme LLC | $135,469 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | An Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent and in Combination with Pembrolizumab Versus Treatm | 2025 |
| 2025-12-31 | Merck Sharp & Dohme LLC | $94,949 | Research payment | In-kind items and services | Drug, ONCOLOGY | MK-5684-003# A Phase 3 Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in | 2025 |
| 2025-12-31 | Merck Sharp & Dohme LLC | $45,333 | Research payment | In-kind items and services | WELIREG Drug, ONCOLOGY | A Multicenter, Open-label, Randomized, Phase 1,2 Study of Belzutifan in Combination with Palbociclib Versus Belzutifan M | 2025 |
| 2025-12-31 | Merck Sharp & Dohme LLC | $34,097 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 1,2 Open-Label Rolling-Arm Umbrella Platform Study of Investigational Agents With or Without Pembrolizumab in P | 2025 |
| 2025-12-31 | Merck Sharp & Dohme LLC | $30,157 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 1,2 Randomized, Umbrella Study to Evaluate the Efficacy and Safety of MK-2870 Plus Enfortumab Vedotin EV With an | 2025 |
| 2025-12-31 | Merck Sharp & Dohme LLC | $21,745 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 1,2 Open-Label Rolling-Arm Umbrella Platform Study of Investigational Agents With or Without Pembrolizumab in P | 2025 |
| 2025-12-31 | Merck Sharp & Dohme LLC | $16,755 | Research payment | In-kind items and services | DEXAMETHASONE Drug, ENDOCRINOLOGY | A Phase 3, Multicenter, Open-label, Randomized Study to Compare the Efficacy and Safety of MK-2870 Versus Treatment of P | 2025 |
| 2025-12-29 | PUMA BIOTECHNOLOGY, INC. | $21,385 | Research payment | Cash or cash equivalent | ALI-1201 | 2025 | |
| 2025-12-26 | Adaptive Biotechnologies Corporation | $600 | Research payment | Cash or cash equivalent | clonoSEQ Device, Devices | 19-0339 | 2025 |
| 2025-12-24 | Syndax Pharmaceuticals, Inc. | $7,258 | Research payment | Cash or cash equivalent | REVUFORJ Drug, HEMATOLOGY-ONCOLOGY | A MASTER PROTOCOL FOR BIOMARKER-BASED TREATMENT OF AML (THE BEAT AML TRIAL) | 2025 |
| 2025-12-24 | Syndax Pharmaceuticals, Inc. | $1,516 | Research payment | Cash or cash equivalent | REVUFORJ Drug, HEMATOLOGY-ONCOLOGY | A MASTER PROTOCOL FOR BIOMARKER-BASED TREATMENT OF AML (THE BEAT AML TRIAL) | 2025 |
| 2025-12-24 | Syndax Pharmaceuticals, Inc. | $1,516 | Research payment | Cash or cash equivalent | REVUFORJ Drug, HEMATOLOGY-ONCOLOGY | A MASTER PROTOCOL FOR BIOMARKER-BASED TREATMENT OF AML (THE BEAT AML TRIAL) | 2025 |
| 2025-12-24 | Syndax Pharmaceuticals, Inc. | $1,516 | Research payment | Cash or cash equivalent | REVUFORJ Drug, HEMATOLOGY-ONCOLOGY | A MASTER PROTOCOL FOR BIOMARKER-BASED TREATMENT OF AML (THE BEAT AML TRIAL) | 2025 |
| 2025-12-21 | Adaptive Biotechnologies Corporation | $600 | Research payment | Cash or cash equivalent | clonoSEQ Device, Devices | 19-0339 | 2025 |
| 2025-12-15 | Adaptive Biotechnologies Corporation | $600 | Research payment | Cash or cash equivalent | clonoSEQ Device, Devices | 19-0339 | 2025 |
| 2025-12-08 | Epizyme, Inc. | $78 | Research payment | Cash or cash equivalent | Tazverik Drug, Oncology | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat | 2025 |
| 2025-12-04 | Novartis Pharmaceuticals Corporation | $3,250 | Research payment | Cash or cash equivalent | A Phase III, Randomized, Double-blind Study of Ianalumab (VAY736) Versus Placebo in Addition to First-line Corticosteroi | 2025 | |
| 2025-12-01 | Epizyme, Inc. | $1,544 | Research payment | Cash or cash equivalent | Tazverik Drug, Oncology | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat | 2025 |
| 2025-12-01 | Epizyme, Inc. | $1,466 | Research payment | Cash or cash equivalent | Tazverik Drug, Oncology | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat | 2025 |
| 2025-12-01 | Epizyme, Inc. | $1,466 | Research payment | Cash or cash equivalent | Tazverik Drug, Oncology | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat | 2025 |
| 2025-12-01 | Epizyme, Inc. | $1,311 | Research payment | Cash or cash equivalent | Tazverik Drug, Oncology | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat | 2025 |
| 2025-12-01 | Epizyme, Inc. | $1,311 | Research payment | Cash or cash equivalent | Tazverik Drug, Oncology | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat | 2025 |
| 2025-12-01 | Epizyme, Inc. | $1,311 | Research payment | Cash or cash equivalent | Tazverik Drug, Oncology | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat | 2025 |
| 2025-12-01 | Epizyme, Inc. | $1,182 | Research payment | Cash or cash equivalent | Tazverik Drug, Oncology | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat | 2025 |
| 2025-12-01 | Epizyme, Inc. | $1,182 | Research payment | Cash or cash equivalent | Tazverik Drug, Oncology | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat | 2025 |
| 2025-12-01 | Epizyme, Inc. | $1,182 | Research payment | Cash or cash equivalent | Tazverik Drug, Oncology | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat | 2025 |
| 2025-12-01 | Epizyme, Inc. | $1,182 | Research payment | Cash or cash equivalent | Tazverik Drug, Oncology | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat | 2025 |
| 2025-12-01 | Epizyme, Inc. | $1,182 | Research payment | Cash or cash equivalent | Tazverik Drug, Oncology | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat | 2025 |
| 2025-12-01 | Epizyme, Inc. | $926 | Research payment | Cash or cash equivalent | Tazverik Drug, Oncology | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat | 2025 |
| 2025-12-01 | Novartis Pharmaceuticals Corporation | $405 | Research payment | In-kind items and services | An Open-label, Multi-center, Phase I Study of Oral IAG933 in Adult Patients With Advanced Mesothelioma and Other Solid T | 2025 | |
| 2025-11-28 | Epizyme, Inc. | $1,544 | Research payment | Cash or cash equivalent | Tazverik Drug, Oncology | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat | 2025 |
| 2025-11-28 | Epizyme, Inc. | $1,466 | Research payment | Cash or cash equivalent | Tazverik Drug, Oncology | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat | 2025 |
| 2025-11-28 | Epizyme, Inc. | $1,182 | Research payment | Cash or cash equivalent | Tazverik Drug, Oncology | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat | 2025 |
| 2025-11-28 | Epizyme, Inc. | $1,182 | Research payment | Cash or cash equivalent | Tazverik Drug, Oncology | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat | 2025 |
| 2025-11-28 | Epizyme, Inc. | $926 | Research payment | Cash or cash equivalent | Tazverik Drug, Oncology | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat | 2025 |
| 2025-11-15 | Novartis Pharmaceuticals Corporation | $91 | Research payment | In-kind items and services | KYMRIAH Drug, Oncology | A single arm phase II trial in first line high risk HR pediatric and young adult patients with Bcell acute lymphoblastic | 2025 |
| 2025-11-14 | PUMA BIOTECHNOLOGY, INC. | $8,370 | Research payment | Cash or cash equivalent | ALI-1201 | 2025 | |
| 2025-11-14 | Adaptive Biotechnologies Corporation | $600 | Research payment | Cash or cash equivalent | clonoSEQ Device, Devices | 19-0339 | 2025 |
| 2025-11-09 | Adaptive Biotechnologies Corporation | $600 | Research payment | Cash or cash equivalent | clonoSEQ Device, Devices | 19-0339 | 2025 |
| 2025-10-30 | Syndax Pharmaceuticals, Inc. | $8,599 | Research payment | Cash or cash equivalent | REVUFORJ Drug, HEMATOLOGY-ONCOLOGY | A MASTER PROTOCOL FOR BIOMARKER-BASED TREATMENT OF AML (THE BEAT AML TRIAL) | 2025 |
| 2025-10-30 | Syndax Pharmaceuticals, Inc. | $2,099 | Research payment | Cash or cash equivalent | REVUFORJ Drug, HEMATOLOGY-ONCOLOGY | A MASTER PROTOCOL FOR BIOMARKER-BASED TREATMENT OF AML (THE BEAT AML TRIAL) | 2025 |
| 2025-10-30 | Syndax Pharmaceuticals, Inc. | $1,516 | Research payment | Cash or cash equivalent | REVUFORJ Drug, HEMATOLOGY-ONCOLOGY | A MASTER PROTOCOL FOR BIOMARKER-BASED TREATMENT OF AML (THE BEAT AML TRIAL) | 2025 |
| 2025-10-08 | Adaptive Biotechnologies Corporation | $600 | Research payment | Cash or cash equivalent | clonoSEQ Device, Devices | 19-0339 | 2025 |
| 2025-10-08 | CSL Behring | $172 | Research payment | In-kind items and services | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcom | 2025 | |
| 2025-10-07 | Adaptive Biotechnologies Corporation | $600 | Research payment | Cash or cash equivalent | clonoSEQ Device, Devices | 19-0339 | 2025 |
| 2025-10-06 | Adaptive Biotechnologies Corporation | $600 | Research payment | Cash or cash equivalent | clonoSEQ Device, Devices | 19-0339 | 2025 |
| 2025-10-03 | Adaptive Biotechnologies Corporation | $600 | Research payment | Cash or cash equivalent | clonoSEQ Device, Devices | 19-0339 | 2025 |
| 2025-10-02 | Adaptive Biotechnologies Corporation | $600 | Research payment | Cash or cash equivalent | clonoSEQ Device, Devices | 19-0339 | 2025 |
| 2025-09-25 | Adaptive Biotechnologies Corporation | $600 | Research payment | Cash or cash equivalent | clonoSEQ Device, Devices | 19-0339 | 2025 |
| 2025-09-24 | Epizyme, Inc. | $2,617 | Research payment | Cash or cash equivalent | Tazverik Drug, Oncology | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat | 2025 |
| 2025-09-24 | Epizyme, Inc. | $2,617 | Research payment | Cash or cash equivalent | Tazverik Drug, Oncology | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat | 2025 |
| 2025-09-24 | Epizyme, Inc. | $2,617 | Research payment | Cash or cash equivalent | Tazverik Drug, Oncology | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat | 2025 |
| 2025-09-24 | Epizyme, Inc. | $1,651 | Research payment | Cash or cash equivalent | Tazverik Drug, Oncology | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat | 2025 |
| 2025-09-24 | Epizyme, Inc. | $1,651 | Research payment | Cash or cash equivalent | Tazverik Drug, Oncology | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat | 2025 |
| 2025-09-24 | Epizyme, Inc. | $1,651 | Research payment | Cash or cash equivalent | Tazverik Drug, Oncology | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat | 2025 |
| 2025-09-24 | Epizyme, Inc. | $1,544 | Research payment | Cash or cash equivalent | Tazverik Drug, Oncology | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat | 2025 |
| 2025-09-24 | Epizyme, Inc. | $1,544 | Research payment | Cash or cash equivalent | Tazverik Drug, Oncology | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat | 2025 |
| 2025-09-24 | Syndax Pharmaceuticals, Inc. | $1,516 | Research payment | Cash or cash equivalent | REVUFORJ Drug, HEMATOLOGY-ONCOLOGY | A MASTER PROTOCOL FOR BIOMARKER-BASED TREATMENT OF AML (THE BEAT AML TRIAL) | 2025 |
| 2025-09-24 | Epizyme, Inc. | $1,466 | Research payment | Cash or cash equivalent | Tazverik Drug, Oncology | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat | 2025 |
| 2025-09-24 | Epizyme, Inc. | $1,311 | Research payment | Cash or cash equivalent | Tazverik Drug, Oncology | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat | 2025 |
| 2025-09-24 | Epizyme, Inc. | $1,238 | Research payment | Cash or cash equivalent | Tazverik Drug, Oncology | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat | 2025 |
| 2025-09-24 | Epizyme, Inc. | $1,238 | Research payment | Cash or cash equivalent | Tazverik Drug, Oncology | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat | 2025 |
| 2025-09-24 | Epizyme, Inc. | $1,238 | Research payment | Cash or cash equivalent | Tazverik Drug, Oncology | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat | 2025 |
| 2025-09-24 | Epizyme, Inc. | $1,182 | Research payment | Cash or cash equivalent | Tazverik Drug, Oncology | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat | 2025 |
| 2025-09-24 | Epizyme, Inc. | $1,182 | Research payment | Cash or cash equivalent | Tazverik Drug, Oncology | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat | 2025 |
| 2025-09-24 | Epizyme, Inc. | $1,182 | Research payment | Cash or cash equivalent | Tazverik Drug, Oncology | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat | 2025 |
| 2025-09-24 | Epizyme, Inc. | $1,182 | Research payment | Cash or cash equivalent | Tazverik Drug, Oncology | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat | 2025 |
| 2025-09-24 | Epizyme, Inc. | $1,182 | Research payment | Cash or cash equivalent | Tazverik Drug, Oncology | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat | 2025 |
| 2025-09-24 | Epizyme, Inc. | $1,182 | Research payment | Cash or cash equivalent | Tazverik Drug, Oncology | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat | 2025 |
| 2025-09-24 | Epizyme, Inc. | $987 | Research payment | Cash or cash equivalent | Tazverik Drug, Oncology | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat | 2025 |
| 2025-09-24 | Epizyme, Inc. | $987 | Research payment | Cash or cash equivalent | Tazverik Drug, Oncology | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat | 2025 |
| 2025-09-24 | Epizyme, Inc. | $987 | Research payment | Cash or cash equivalent | Tazverik Drug, Oncology | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat | 2025 |
| 2025-09-24 | Epizyme, Inc. | $926 | Research payment | Cash or cash equivalent | Tazverik Drug, Oncology | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat | 2025 |
| 2025-09-24 | Epizyme, Inc. | $926 | Research payment | Cash or cash equivalent | Tazverik Drug, Oncology | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat | 2025 |
| 2025-09-24 | Epizyme, Inc. | $874 | Research payment | Cash or cash equivalent | Tazverik Drug, Oncology | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat | 2025 |
| 2025-09-24 | Epizyme, Inc. | $874 | Research payment | Cash or cash equivalent | Tazverik Drug, Oncology | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat | 2025 |
| 2025-09-24 | Epizyme, Inc. | $874 | Research payment | Cash or cash equivalent | Tazverik Drug, Oncology | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat | 2025 |
| 2025-09-24 | Epizyme, Inc. | $651 | Research payment | Cash or cash equivalent | Tazverik Drug, Oncology | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat | 2025 |
| 2025-09-24 | Epizyme, Inc. | $651 | Research payment | Cash or cash equivalent | Tazverik Drug, Oncology | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat | 2025 |
| 2025-09-24 | Epizyme, Inc. | $651 | Research payment | Cash or cash equivalent | Tazverik Drug, Oncology | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat | 2025 |
| 2025-09-22 | CSL Behring | $1,764 | Research payment | In-kind items and services | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcom | 2025 | |
| 2025-09-14 | Adaptive Biotechnologies Corporation | $600 | Research payment | Cash or cash equivalent | clonoSEQ Device, Devices | 19-0339 | 2025 |
| 2025-09-10 | Adaptive Biotechnologies Corporation | $600 | Research payment | Cash or cash equivalent | clonoSEQ Device, Devices | 19-0339 | 2025 |
| 2025-09-06 | Adaptive Biotechnologies Corporation | $600 | Research payment | Cash or cash equivalent | clonoSEQ Device, Devices | 19-0339 | 2025 |
| 2025-09-02 | Adaptive Biotechnologies Corporation | $600 | Research payment | Cash or cash equivalent | clonoSEQ Device, Devices | 19-0339 | 2025 |
| 2025-08-31 | Merck Sharp & Dohme LLC | $116,236 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 1,2 Study of V940 Plus Pembrolizumab With or Without Enfortumab Vedotin in Muscle-Invasive Urothelial Carcinoma | 2025 |
| 2025-08-31 | Merck Sharp & Dohme LLC | $33,210 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3 Study of Pembrolizumab in combination with Carboplatin,Taxane Paclitaxel or Nab-paclitaxel followed by Pembrol | 2025 |
| 2025-08-29 | Epizyme, Inc. | $78 | Research payment | Cash or cash equivalent | Tazverik Drug, Oncology | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat | 2025 |
| 2025-08-21 | Syndax Pharmaceuticals, Inc. | $8,599 | Research payment | Cash or cash equivalent | REVUFORJ Drug, HEMATOLOGY-ONCOLOGY | A MASTER PROTOCOL FOR BIOMARKER-BASED TREATMENT OF AML (THE BEAT AML TRIAL) | 2025 |
| 2025-08-21 | Syndax Pharmaceuticals, Inc. | $7,258 | Research payment | Cash or cash equivalent | REVUFORJ Drug, HEMATOLOGY-ONCOLOGY | A MASTER PROTOCOL FOR BIOMARKER-BASED TREATMENT OF AML (THE BEAT AML TRIAL) | 2025 |
| 2025-08-21 | Syndax Pharmaceuticals, Inc. | $2,099 | Research payment | Cash or cash equivalent | REVUFORJ Drug, HEMATOLOGY-ONCOLOGY | A MASTER PROTOCOL FOR BIOMARKER-BASED TREATMENT OF AML (THE BEAT AML TRIAL) | 2025 |
| 2025-08-21 | Syndax Pharmaceuticals, Inc. | $1,516 | Research payment | Cash or cash equivalent | REVUFORJ Drug, HEMATOLOGY-ONCOLOGY | A MASTER PROTOCOL FOR BIOMARKER-BASED TREATMENT OF AML (THE BEAT AML TRIAL) | 2025 |
| 2025-08-21 | Syndax Pharmaceuticals, Inc. | $302 | Research payment | Cash or cash equivalent | REVUFORJ Drug, HEMATOLOGY-ONCOLOGY | A MASTER PROTOCOL FOR BIOMARKER-BASED TREATMENT OF AML (THE BEAT AML TRIAL) | 2025 |
| 2025-08-21 | Syndax Pharmaceuticals, Inc. | $302 | Research payment | Cash or cash equivalent | REVUFORJ Drug, HEMATOLOGY-ONCOLOGY | A MASTER PROTOCOL FOR BIOMARKER-BASED TREATMENT OF AML (THE BEAT AML TRIAL) | 2025 |
| 2025-08-21 | Syndax Pharmaceuticals, Inc. | $302 | Research payment | Cash or cash equivalent | REVUFORJ Drug, HEMATOLOGY-ONCOLOGY | A MASTER PROTOCOL FOR BIOMARKER-BASED TREATMENT OF AML (THE BEAT AML TRIAL) | 2025 |
| 2025-08-21 | Syndax Pharmaceuticals, Inc. | $302 | Research payment | Cash or cash equivalent | REVUFORJ Drug, HEMATOLOGY-ONCOLOGY | A MASTER PROTOCOL FOR BIOMARKER-BASED TREATMENT OF AML (THE BEAT AML TRIAL) | 2025 |
| 2025-08-14 | Adaptive Biotechnologies Corporation | $1,200 | Research payment | Cash or cash equivalent | clonoSEQ Device, Devices | 19-0339 | 2025 |
| 2025-08-13 | Epizyme, Inc. | $78 | Research payment | Cash or cash equivalent | Tazverik Drug, Oncology | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat | 2025 |
| 2025-07-28 | Epizyme, Inc. | $156 | Research payment | Cash or cash equivalent | Tazverik Drug, Oncology | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat | 2025 |
| 2025-07-08 | Adaptive Biotechnologies Corporation | $600 | Research payment | Cash or cash equivalent | clonoSEQ Device, Devices | 19-0339 | 2025 |
| 2025-06-28 | Adaptive Biotechnologies Corporation | $600 | Research payment | Cash or cash equivalent | clonoSEQ Device, Devices | 19-0339 | 2025 |
| 2025-06-20 | Adaptive Biotechnologies Corporation | $31,200 | Research payment | Cash or cash equivalent | immunoSEQ Device, Devices | 19-0339_R | 2025 |
| 2025-06-18 | Epizyme, Inc. | $1,651 | Research payment | Cash or cash equivalent | Tazverik Drug, Oncology | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat | 2025 |
| 2025-06-18 | Syndax Pharmaceuticals, Inc. | $1,516 | Research payment | Cash or cash equivalent | REVUFORJ Drug, HEMATOLOGY-ONCOLOGY | A MASTER PROTOCOL FOR BIOMARKER-BASED TREATMENT OF AML (THE BEAT AML TRIAL) | 2025 |
| 2025-06-16 | Epizyme, Inc. | $4,096 | Research payment | Cash or cash equivalent | Tazverik Drug, Oncology | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat | 2025 |
| 2025-06-16 | Epizyme, Inc. | $2,560 | Research payment | Cash or cash equivalent | Tazverik Drug, Oncology | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat | 2025 |
| 2025-06-16 | Epizyme, Inc. | $2,560 | Research payment | Cash or cash equivalent | Tazverik Drug, Oncology | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat | 2025 |
| 2025-06-16 | Epizyme, Inc. | $1,536 | Research payment | Cash or cash equivalent | Tazverik Drug, Oncology | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat | 2025 |
| 2025-06-16 | Epizyme, Inc. | $650 | Research payment | Cash or cash equivalent | Tazverik Drug, Oncology | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat | 2025 |
| 2025-06-16 | Epizyme, Inc. | $650 | Research payment | Cash or cash equivalent | Tazverik Drug, Oncology | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat | 2025 |
| 2025-06-16 | Epizyme, Inc. | $650 | Research payment | Cash or cash equivalent | Tazverik Drug, Oncology | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat | 2025 |
| 2025-06-16 | Epizyme, Inc. | $67 | Research payment | Cash or cash equivalent | Tazverik Drug, Oncology | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat | 2025 |
| 2025-06-04 | Epizyme, Inc. | $1,603 | Research payment | Cash or cash equivalent | Tazverik Drug, Oncology | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat | 2025 |
| 2025-06-04 | Epizyme, Inc. | $509 | Research payment | Cash or cash equivalent | Tazverik Drug, Oncology | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat | 2025 |
| 2025-06-02 | Adaptive Biotechnologies Corporation | $600 | Research payment | Cash or cash equivalent | clonoSEQ Device, Devices | 19-0339 | 2025 |
| 2025-05-23 | Syndax Pharmaceuticals, Inc. | $1,516 | Research payment | Cash or cash equivalent | REVUFORJ Drug, HEMATOLOGY-ONCOLOGY | A MASTER PROTOCOL FOR BIOMARKER-BASED TREATMENT OF AML (THE BEAT AML TRIAL) | 2025 |
| 2025-05-23 | Syndax Pharmaceuticals, Inc. | $1,516 | Research payment | Cash or cash equivalent | REVUFORJ Drug, HEMATOLOGY-ONCOLOGY | A MASTER PROTOCOL FOR BIOMARKER-BASED TREATMENT OF AML (THE BEAT AML TRIAL) | 2025 |
| 2025-05-23 | Syndax Pharmaceuticals, Inc. | $302 | Research payment | Cash or cash equivalent | REVUFORJ Drug, HEMATOLOGY-ONCOLOGY | A MASTER PROTOCOL FOR BIOMARKER-BASED TREATMENT OF AML (THE BEAT AML TRIAL) | 2025 |
| 2025-05-23 | Syndax Pharmaceuticals, Inc. | $302 | Research payment | Cash or cash equivalent | REVUFORJ Drug, HEMATOLOGY-ONCOLOGY | A MASTER PROTOCOL FOR BIOMARKER-BASED TREATMENT OF AML (THE BEAT AML TRIAL) | 2025 |
| 2025-05-20 | Adaptive Biotechnologies Corporation | $600 | Research payment | Cash or cash equivalent | clonoSEQ Device, Devices | 19-0339 | 2025 |
| 2025-04-30 | Epizyme, Inc. | $2,827 | Research payment | Cash or cash equivalent | Tazverik Drug, Oncology | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat | 2025 |
| 2025-04-30 | Epizyme, Inc. | $2,827 | Research payment | Cash or cash equivalent | Tazverik Drug, Oncology | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat | 2025 |
| 2025-04-30 | Epizyme, Inc. | $1,416 | Research payment | Cash or cash equivalent | Tazverik Drug, Oncology | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat | 2025 |
| 2025-04-30 | Epizyme, Inc. | $1,297 | Research payment | Cash or cash equivalent | Tazverik Drug, Oncology | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat | 2025 |
| 2025-04-30 | Epizyme, Inc. | $1,182 | Research payment | Cash or cash equivalent | Tazverik Drug, Oncology | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat | 2025 |
| 2025-04-30 | Epizyme, Inc. | $1,124 | Research payment | Cash or cash equivalent | Tazverik Drug, Oncology | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat | 2025 |
| 2025-04-29 | Adaptive Biotechnologies Corporation | $600 | Research payment | Cash or cash equivalent | clonoSEQ Device, Devices | 19-0339 | 2025 |
| 2025-04-25 | Adaptive Biotechnologies Corporation | $600 | Research payment | Cash or cash equivalent | clonoSEQ Device, Devices | 19-0339 | 2025 |
| 2025-04-21 | Adaptive Biotechnologies Corporation | $600 | Research payment | Cash or cash equivalent | clonoSEQ Device, Devices | 19-0339 | 2025 |
| 2025-04-19 | Adaptive Biotechnologies Corporation | $600 | Research payment | Cash or cash equivalent | clonoSEQ Device, Devices | 19-0339 | 2025 |
| 2025-04-18 | Adaptive Biotechnologies Corporation | $600 | Research payment | Cash or cash equivalent | clonoSEQ Device, Devices | 19-0339 | 2025 |
| 2025-04-02 | Adaptive Biotechnologies Corporation | $600 | Research payment | Cash or cash equivalent | clonoSEQ Device, Devices | 19-0339 | 2025 |
| 2025-04-01 | Adaptive Biotechnologies Corporation | $600 | Research payment | Cash or cash equivalent | clonoSEQ Device, Devices | 19-0339 | 2025 |
| 2025-03-31 | Adaptive Biotechnologies Corporation | $600 | Research payment | Cash or cash equivalent | clonoSEQ Device, Devices | 19-0339 | 2025 |
| 2025-03-28 | Adaptive Biotechnologies Corporation | $600 | Research payment | Cash or cash equivalent | clonoSEQ Device, Devices | 19-0339 | 2025 |
| 2025-03-24 | Epizyme, Inc. | $1,064 | Research payment | Cash or cash equivalent | Tazverik Drug, Oncology | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat | 2025 |
| 2025-03-21 | Adaptive Biotechnologies Corporation | $600 | Research payment | Cash or cash equivalent | clonoSEQ Device, Devices | 19-0339 | 2025 |
| 2025-03-20 | Epizyme, Inc. | $1,651 | Research payment | Cash or cash equivalent | Tazverik Drug, Oncology | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat | 2025 |
| 2025-03-20 | Epizyme, Inc. | $1,124 | Research payment | Cash or cash equivalent | Tazverik Drug, Oncology | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat | 2025 |
| 2025-03-14 | PUMA BIOTECHNOLOGY, INC. | $53,757 | Research payment | Cash or cash equivalent | ALI-1201 | 2025 | |
| 2025-03-13 | Adaptive Biotechnologies Corporation | $600 | Research payment | Cash or cash equivalent | clonoSEQ Device, Devices | 19-0339 | 2025 |
| 2025-03-11 | Adaptive Biotechnologies Corporation | $600 | Research payment | Cash or cash equivalent | clonoSEQ Device, Devices | 19-0339 | 2025 |
| 2025-03-07 | Epizyme, Inc. | $156 | Research payment | Cash or cash equivalent | Tazverik Drug, Oncology | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat | 2025 |
| 2025-03-05 | Adaptive Biotechnologies Corporation | $600 | Research payment | Cash or cash equivalent | clonoSEQ Device, Devices | 19-0339 | 2025 |
| 2025-03-03 | Adaptive Biotechnologies Corporation | $600 | Research payment | Cash or cash equivalent | clonoSEQ Device, Devices | 19-0339 | 2025 |
| 2025-03-02 | Adaptive Biotechnologies Corporation | $600 | Research payment | Cash or cash equivalent | clonoSEQ Device, Devices | 19-0339 | 2025 |
| 2025-03-01 | Adaptive Biotechnologies Corporation | $600 | Research payment | Cash or cash equivalent | clonoSEQ Device, Devices | 19-0339 | 2025 |
| 2025-02-23 | Adaptive Biotechnologies Corporation | $600 | Research payment | Cash or cash equivalent | clonoSEQ Device, Devices | 19-0339 | 2025 |
| 2025-02-11 | CSL Behring | $1,011 | Research payment | In-kind items and services | A Phase 2b, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose Range Finding Study to Evalu | 2025 | |
| 2025-02-10 | Novartis Pharmaceuticals Corporation | $63,844 | Research payment | Cash or cash equivalent | A Phase 3 Randomized, Double-blind Study of Ianalumab (VAY736) Versus Placebo in Addition to Eltrombopag in Patients Wit | 2025 | |
| 2025-02-05 | Epizyme, Inc. | $2,827 | Research payment | Cash or cash equivalent | Tazverik Drug, Oncology | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat | 2025 |
| 2025-02-05 | Epizyme, Inc. | $1,297 | Research payment | Cash or cash equivalent | Tazverik Drug, Oncology | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat | 2025 |
| 2025-02-05 | Epizyme, Inc. | $509 | Research payment | Cash or cash equivalent | Tazverik Drug, Oncology | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat | 2025 |
| 2025-02-02 | Adaptive Biotechnologies Corporation | $1,200 | Research payment | Cash or cash equivalent | clonoSEQ Device, Devices | 19-0339 | 2025 |
| 2025-01-30 | Iovance Biotherapeutics, Inc. | $48,442 | Research payment | Cash or cash equivalent | Amtagvi Drug, Oncology | NCT05361174 | 2025 |
| 2025-01-19 | Adaptive Biotechnologies Corporation | $600 | Research payment | Cash or cash equivalent | clonoSEQ Device, Devices | 19-0339 | 2025 |
| 2025-01-17 | Adaptive Biotechnologies Corporation | $600 | Research payment | Cash or cash equivalent | clonoSEQ Device, Devices | 19-0339 | 2025 |
| 2025-01-15 | Novartis Pharmaceuticals Corporation | $459 | Research payment | In-kind items and services | KYMRIAH Drug, Oncology | A single arm phase II trial in first line high risk HR pediatric and young adult patients with Bcell acute lymphoblastic | 2025 |
| 2025-01-10 | E.R. Squibb & Sons, L.L.C. | $21,500 | Research payment | Cash or cash equivalent | OPDIVO Biological, Oncology | A Phase 3, Randomized, Double-blind Study of Neoadjuvant Chemotherapy plus Nivolumab versus Neoadjuvant Chemotherapy plu | 2025 |
| 2025-01-09 | Novartis Pharmaceuticals Corporation | $96,033 | Research payment | Cash or cash equivalent | A Phase III, Randomized, Double-blind Study of Ianalumab (VAY736) Versus Placebo in Addition to First-line Corticosteroi | 2025 | |
| 2025-01-07 | E.R. Squibb & Sons, L.L.C. | $11,280 | Research payment | Cash or cash equivalent | OPDIVO Biological, Oncology | Randomized, Open-Label, Phase 3 Trial of Nivolumab plus Ipilimumab or Nivolumab plus Platinum-Doublet Chemotherapy versu | 2025 |
| 2025-01-06 | Merck Sharp & Dohme LLC | $20,000 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase 1,2 Randomized, Umbrella Study to Evaluate the Efficacy and Safety of MK-2870 Plus Enfortumab Vedotin EV With an | 2025 |
| 2025-01-01 | Novartis Pharmaceuticals Corporation | $4,376 | Research payment | In-kind items and services | An Open-label, Multi-center, Phase I Study of Oral IAG933 in Adult Patients With Advanced Mesothelioma and Other Solid T | 2025 | |
| 2024-12-31 | Merck Sharp & Dohme LLC | $441,684 | Research payment | In-kind items and services | WELIREG Drug, ONCOLOGY | A Multicenter, Open-label, Randomized, Phase 1,2 Study of Belzutifan in Combination with Palbociclib Versus Belzutifan M | 2024 |
| 2024-12-31 | Merck Sharp & Dohme LLC | $66,420 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 1,2 Study of V940 Plus Pembrolizumab With or Without Enfortumab Vedotin in Muscle-Invasive Urothelial Carcinoma | 2024 |
| 2024-12-31 | Merck Sharp & Dohme LLC | $43,411 | Research payment | In-kind items and services | Drug, ONCOLOGY | A Phase 3 Randomized, Open-label Study of MK-5684 versus Alternative Abiraterone Acetate or Enzalutamide in Participants | 2024 |
| 2024-12-31 | Merck Sharp & Dohme LLC | $41,732 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 1,2 Randomized, Umbrella Study to Evaluate the Safety and Efficacy of Pembrolizumab plus Enfortumab Vedotin EV i | 2024 |
| 2024-12-31 | Merck Sharp & Dohme LLC | $29,496 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 1,2 Randomized, Umbrella Study to Evaluate the Efficacy and Safety of MK-2870 Plus Enfortumab Vedotin EV in Comb | 2024 |
| 2024-12-31 | Merck Sharp & Dohme LLC | $25,614 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 1,2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab in P | 2024 |
| 2024-12-31 | Merck Sharp & Dohme LLC | $14,182 | Research payment | In-kind items and services | WELIREG Drug, ONCOLOGY | A Multicenter, Open-label, Randomized, Phase 1,2 Study of Belzutifan in Combination with Palbociclib Versus Belzutifan M | 2024 |
| 2024-12-16 | Adaptive Biotechnologies Corporation | $600 | Research payment | Cash or cash equivalent | clonoSEQ Device, ONCOLOGY | A Multimodality Approach to Minimal Residual Disease Detection to Guide Post-Transplant Maintenance Therapy in Multiple | 2024 |
| 2024-12-14 | Adaptive Biotechnologies Corporation | $600 | Research payment | Cash or cash equivalent | clonoSEQ Device, ONCOLOGY | A Multimodality Approach to Minimal Residual Disease Detection to Guide Post-Transplant Maintenance Therapy in Multiple | 2024 |
| 2024-12-03 | Boston Scientific Corporation | $4,303 | Research payment | Cash or cash equivalent | Precision Device, Precision_NMD | Paresthesia-Free Fast-Acting Subperception Study | 2024 |
| 2024-12-02 | Adaptive Biotechnologies Corporation | $600 | Research payment | Cash or cash equivalent | clonoSEQ Device, ONCOLOGY | A Multimodality Approach to Minimal Residual Disease Detection to Guide Post-Transplant Maintenance Therapy in Multiple | 2024 |
| 2024-11-30 | Adaptive Biotechnologies Corporation | $600 | Research payment | Cash or cash equivalent | clonoSEQ Device, ONCOLOGY | A Multimodality Approach to Minimal Residual Disease Detection to Guide Post-Transplant Maintenance Therapy in Multiple | 2024 |
| 2024-11-05 | Boston Scientific Corporation | $2,799 | Research payment | Cash or cash equivalent | Precision Device, Precision_NMD | Paresthesia-Free Fast-Acting Subperception Study | 2024 |
| 2024-10-17 | Adaptive Biotechnologies Corporation | $600 | Research payment | Cash or cash equivalent | clonoSEQ Device, ONCOLOGY | A Multimodality Approach to Minimal Residual Disease Detection to Guide Post-Transplant Maintenance Therapy in Multiple | 2024 |
| 2024-10-08 | Boston Scientific Corporation | $7,754 | Research payment | Cash or cash equivalent | Precision Device, Precision_NMD | Paresthesia-Free Fast-Acting Subperception Study | 2024 |
| 2024-10-02 | PFIZER INC. | $2,388 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | A DOSEESCALATION AND DOSEEXPANSION STUDY OF ENFORTUMAB VEDOTIN ASG22CE IN COMBINATION WITH PEMBROLIZUMAB ANDOR CHEMOTHER | 2024 |
| 2024-09-26 | Adaptive Biotechnologies Corporation | $600 | Research payment | Cash or cash equivalent | clonoSEQ Device, ONCOLOGY | A Multimodality Approach to Minimal Residual Disease Detection to Guide Post-Transplant Maintenance Therapy in Multiple | 2024 |
| 2024-09-15 | Adaptive Biotechnologies Corporation | $600 | Research payment | Cash or cash equivalent | clonoSEQ Device, ONCOLOGY | A Multimodality Approach to Minimal Residual Disease Detection to Guide Post-Transplant Maintenance Therapy in Multiple | 2024 |
| 2024-09-10 | Boston Scientific Corporation | $3,900 | Research payment | Cash or cash equivalent | Precision Device, Precision_NMD | Paresthesia-Free Fast-Acting Subperception Study | 2024 |
| 2024-08-28 | Epizyme, Inc. | $1,525 | Research payment | Cash or cash equivalent | Tazverik Drug, Oncology | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat | 2024 |
| 2024-08-28 | Epizyme, Inc. | $1,466 | Research payment | Cash or cash equivalent | Tazverik Drug, Oncology | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat | 2024 |
| 2024-08-28 | Epizyme, Inc. | $1,182 | Research payment | Cash or cash equivalent | Tazverik Drug, Oncology | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat | 2024 |
| 2024-08-26 | Adaptive Biotechnologies Corporation | $1,200 | Research payment | Cash or cash equivalent | clonoSEQ Device, ONCOLOGY | A Multimodality Approach to Minimal Residual Disease Detection to Guide Post-Transplant Maintenance Therapy in Multiple | 2024 |
| 2024-08-24 | Adaptive Biotechnologies Corporation | $600 | Research payment | Cash or cash equivalent | clonoSEQ Device, ONCOLOGY | A Multimodality Approach to Minimal Residual Disease Detection to Guide Post-Transplant Maintenance Therapy in Multiple | 2024 |
| 2024-08-19 | Adaptive Biotechnologies Corporation | $600 | Research payment | Cash or cash equivalent | clonoSEQ Device, ONCOLOGY | A Multimodality Approach to Minimal Residual Disease Detection to Guide Post-Transplant Maintenance Therapy in Multiple | 2024 |
| 2024-08-16 | Epizyme, Inc. | $78 | Research payment | Cash or cash equivalent | Tazverik Drug, Oncology | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat | 2024 |
| 2024-08-13 | Boston Scientific Corporation | $4,879 | Research payment | Cash or cash equivalent | Precision Device, Precision_NMD | Paresthesia-Free Fast-Acting Subperception Study | 2024 |
| 2024-08-12 | Adaptive Biotechnologies Corporation | $1,200 | Research payment | Cash or cash equivalent | clonoSEQ Device, ONCOLOGY | A Multimodality Approach to Minimal Residual Disease Detection to Guide Post-Transplant Maintenance Therapy in Multiple | 2024 |
| 2024-08-07 | PFIZER INC. | $4,768 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | A DOSEESCALATION AND DOSEEXPANSION STUDY OF ENFORTUMAB VEDOTIN ASG22CE IN COMBINATION WITH PEMBROLIZUMAB ANDOR CHEMOTHER | 2024 |
| 2024-07-23 | Adaptive Biotechnologies Corporation | $19,200 | Research payment | Cash or cash equivalent | immunoSEQ Device, ONCOLOGY | A Multimodality Approach to Minimal Residual Disease Detection to Guide Post-Transplant Maintenance Therapy in Multiple | 2024 |
| 2024-07-19 | Adaptive Biotechnologies Corporation | $35,400 | Research payment | Cash or cash equivalent | immunoSEQ Device, ONCOLOGY | Open-label, Single-arm, Phase 2 Study of Initial Treatment With Daratumumab (Darzalex), Carfilzomib (Kyprolis), Lenalido | 2024 |
| 2024-07-10 | PFIZER INC. | $5,500 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | A DOSEESCALATION AND DOSEEXPANSION STUDY OF ENFORTUMAB VEDOTIN ASG22CE IN COMBINATION WITH PEMBROLIZUMAB ANDOR CHEMOTHER | 2024 |
| 2024-07-05 | Adaptive Biotechnologies Corporation | $600 | Research payment | Cash or cash equivalent | clonoSEQ Device, ONCOLOGY | A Multimodality Approach to Minimal Residual Disease Detection to Guide Post-Transplant Maintenance Therapy in Multiple | 2024 |
| 2024-07-03 | Adaptive Biotechnologies Corporation | $600 | Research payment | Cash or cash equivalent | clonoSEQ Device, ONCOLOGY | A Multimodality Approach to Minimal Residual Disease Detection to Guide Post-Transplant Maintenance Therapy in Multiple | 2024 |
| 2024-07-02 | Adaptive Biotechnologies Corporation | $600 | Research payment | Cash or cash equivalent | clonoSEQ Device, ONCOLOGY | A Multimodality Approach to Minimal Residual Disease Detection to Guide Post-Transplant Maintenance Therapy in Multiple | 2024 |
| 2024-06-24 | ABBVIE INC. | $9,250 | Research payment | In-kind items and services | VENCLEXTA Drug, ONCOLOGY | Phase 1b Study of Venetoclax in Combination with Intensive Induction and Consolidation Chemotherapy in Treatment Naive S | 2024 |
The latest 200 records of 752.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Chicago, IL, county Cook County, IL, state Illinois; placed by its city name.
| Measure | Place (city or town) Chicago, IL | County Cook County, IL | State Illinois |
|---|---|---|---|
| Population B01003 | 2,711,226 | 5,182,090 | 12,694,798 |
| Population, 2020 census P1 | 2,746,388 | 5,275,541 | 12,812,508 |
| Median age B01002 | 35.8 | 38.0 | 39.0 |
| Under 18 B01001 | 19.4% | 21.1% | 21.8% |
| 65 and over B01001 | 13.8% | 16.0% | 17.0% |
| Households B11001 | 1,160,205 | 2,100,230 | 5,036,449 |
| Foreign born B05002 | 20.9% | 21.7% | 14.7% |
| Median household income B19013 | $77,902 | $83,498 | $83,390 |
| Median family income B19113 | $95,774 | $104,836 | $106,018 |
| Per capita income B19301 | $50,086 | $49,329 | $46,406 |
| Poverty rate B17001 | 16.8% | 13.5% | 11.8% |
| Unemployment rate B23025 | 8.0% | 7.0% | 5.8% |
| Civilian labor force B23025 | 1,517,330 | 2,792,888 | 6,652,134 |
| Mean commute (minutes) B08013 | 33.1 | 31.5 | 27.8 |
| Bachelor's degree or higher B15003 | 44.3% | 42.7% | 37.8% |
| Housing units B25001 | 1,277,054 | 2,276,493 | 5,457,452 |
| Owner-occupied B25003 | 46.0% | 57.7% | 67.1% |
| Renters B25003 | 54.0% | 42.3% | 32.9% |
| Median home value B25077 | $334,100 | $324,500 | $263,300 |
| Median gross rent B25064 | $1,440 | $1,435 | $1,274 |
| White, not Hispanic B03002 | 32.1% | 40.1% | 58.1% |
| Black B03002 | 27.4% | 21.8% | 13.3% |
| Hispanic or Latino B03002 | 29.7% | 26.8% | 18.8% |
| Asian B03002 | 7.2% | 7.9% | 5.9% |
| American Indian and Alaska Native B03002 | 0.1% | 0.1% | 0.1% |
Economy now FRED unemployment 4.6% in Sep 2026 (4.5% a year earlier); per capita personal income $78,987 in 2025, up 28% in five years (+3.1% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Chicago, IL.
Comments